# CJC-1295 Dosage in the Literature: Doses, Routes, and Half-Life

> CJC-1295 dosage as logged in research: single subcutaneous doses of 30, 60, or 90 µg/kg in human PK studies; 2 µg per dose in GHRH-knockout mice. No approved human dose exists.

Which doses were administered to which species, by which route, in the published record — research context only, with no human protocol implied.

## What doses the studies administered

CJC-1295 dosage in the published literature is a short, specific list. Human pharmacokinetic studies used single subcutaneous doses of 30, 60, or 90 µg/kg [1][3]. In the GHRH-knockout mouse growth study, 2 µg per dose was given at 24-, 48-, or 72-hour intervals [7]. That is the controlled-research record. There is no approved human dose for CJC-1295 anywhere, and the fixed-microgram "protocols" that circulate in community settings — typically cited in the 100-300 µg range for the no-DAC form or for CJC-1295/ipamorelin combinations — are not derived from controlled human trials.

This page describes what was administered to whom in research. It is not a recommendation, a titration schedule, or a protocol. Doses are reported as study parameters, expressed per kilogram of body weight or as absolute amounts exactly as the papers reported them.

## Half-life and duration in research handling

Duration is where the DAC and no-DAC forms diverge sharply. The CJC-1295 DAC estimated half-life in healthy adults was 5.8 to 8.1 days, and IGF-1 elevation persisted up to 28 days after multiple doses [1]. The albumin-conjugation chemistry is the reason: a single dose stays in circulation for days because the peptide rides covalently on serum albumin [2]. The no-DAC Modified GRF (1-29) form is short-acting, clearing on a minutes-to-hours scale that mirrors native GHRH(1-29) with protease-resistant substitutions. In a GHRH-knockout mouse, once-daily CJC-1295 (2 µg) fully normalized body weight and length, while dosing every 48-72 hours was progressively less effective — a direct demonstration that the long-acting analog's once-daily schedule was sufficient to restore GH-axis-dependent growth in that model [7].

## Routes and handling in the studies

All human and animal CJC-1295 studies used subcutaneous injection; early GRF(1-29) pharmacokinetic work also used the intravenous route [1][2]. The compound is not orally bioavailable — as a peptide it is degraded in the gut — so subcutaneous injection is the route the literature reports. In research handling, CJC-1295 is supplied as a lyophilized (freeze-dried) peptide, reconstituted with bacteriostatic water, and refrigerated. The four substitutions confer DPP-IV and general protease resistance; the DAC conjugation confers the multi-day duration.

---

A night-tracker readout of the CJC-1295 record — every GH and IGF-1 figure logged to its study like a recovery stat, the DAC-versus-no-DAC half-life kept on separate rings, and the missing human-safety data left openly blank; no clinic behind the tracker and nothing here dispensed or sold.